Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer

Fig. 5

Overall survival analysis in advanced-stage patients who received or did not receive angiogenesis inhibitors. Patients were grouped according to initial angiogenesis-related MR-PET parameters, i.e., (a) metabolic tumor volume (MTV) ≥ 30 or (b) < 30 cm3, (c) Ktrans ≥ 200 or (d) < 200 (10− 3 min− 1), and (e) kep ≥ 900 or (f) < 900 (10− 3 min− 1). P-values were determined using Kaplan–Meier log-rank tests

Back to article page